Quick answer: BPC-157 is a synthetic pentadecapeptide, a chain of fifteen amino acids, based on a sequence identified in a protein found in human gastric juice. Nearly all of the evidence behind it comes from rodent studies, and controlled human trial evidence is essentially absent. In 2023 the FDA placed BPC-157 in the category of substances that raise significant safety risks for use in compounding, which means licensed compounding pharmacies are not able to supply it in the way many websites imply, and it is also prohibited in sport. Everhuman does not offer BPC-157, and this page is a reference only.
BPC-157 has more grey-market marketing behind it than almost any other peptide, which is precisely why an accurate account is worth writing. The compound is real, the rodent literature is genuinely extensive, and the gap between that literature and what is known about humans is very wide. Both of those facts belong in the same description.
What BPC-157 is
BPC-157 is a synthetic peptide of fifteen amino acids, described in the research literature as a partial sequence derived from body protection compound, a protein isolated from human gastric juice. Whether the parent protein exists as described has itself been questioned by some reviewers, since much of the original characterisation comes from a small number of research groups. The synthetic peptide, however, is a defined and reproducible molecule.
Peptide length matters for how a compound behaves, and fifteen amino acids is short. If the vocabulary in this paragraph is unfamiliar, the background piece on what peptides are and how they differ from proteins covers the basics this page builds on.
The proposed mechanism
Mechanistic explanations for BPC-157 in the literature centre on angiogenesis, the formation of new blood vessels, and on interactions with growth factor signalling and nitric oxide pathways. Animal work has also described effects on tendon and ligament cell migration in culture and on markers of gastrointestinal mucosal integrity. Several proposed mechanisms are offered rather than one settled account, which is itself informative.
Multiple competing mechanisms usually indicate an early and unsettled research picture. A well-characterised drug tends to have a specific molecular target and a description of how it engages that target; BPC-157 does not yet have that, and the receptor through which it would act has not been definitively identified. Mechanism proposals are therefore descriptions of observed effects rather than explanations of them.
What the rodent evidence shows, and what it cannot tell you
Rodent studies form the overwhelming majority of BPC-157 research, and there are many of them. Published models include tendon and ligament injury, muscle injury, gastrointestinal lesions, and various forms of tissue damage, with reported findings that researchers characterise as favourable across a wide range of injury types. The breadth of that reported activity is often presented as a strength.
Breadth is arguably the more concerning feature. A compound reported to improve outcomes in nearly every animal injury model it is tested in, across many organ systems, is a pattern that experienced reviewers view cautiously, because it can reflect publication and reporting patterns as much as underlying biology. Much of the work also comes from a relatively small set of collaborating research groups, which limits independent replication.
Human evidence, meanwhile, is close to nonexistent. No adequately powered, controlled human trial has established that BPC-157 improves any clinical outcome, and the long-term safety profile in people has not been characterised. Anyone reading a page that cites dozens of studies should check the species line in each one, a habit the guide on how to read peptide evidence without being misled explains in more detail.
The FDA compounding decision, stated plainly
BPC-157 cannot be legitimately supplied by a licensed compounding pharmacy in the United States. In 2023 the FDA placed BPC-157 in category 2 of its bulk drug substances review, the category for substances that raise significant safety risks for use in compounding, and the agency has stated that it is not aware of adequate data to evaluate its safety. Compounding outsourcing facilities and pharmacies operating within the rules therefore do not compound it.
Marketing that describes BPC-157 as a compounded prescription peptide is consequently describing something the licensed system does not provide. Material available in practice is sold as research chemical, labelled not for human consumption, from vendors outside pharmacy regulation, with no independent verification of identity, purity or sterility. The distinction between those two supply routes is set out in the comparison of research-labelled peptides and prescription products.
Prohibited in sport
BPC-157 is prohibited by the World Anti-Doping Agency and is banned both in and out of competition. WADA added it explicitly to the Prohibited List, and it has appeared in anti-doping cases involving tested athletes. Anyone competing under WADA-aligned rules should regard the compound as a violation regardless of how a vendor labels the product.
Prohibited status is sometimes presented in marketing as evidence that something works, which is a misreading. Listing reflects a regulatory judgement that a substance may affect performance and is in circulation, and says nothing about whether it is safe or effective in a general population.
How to read BPC-157 marketing
BPC-157 marketing tends to lean on three moves worth recognising. Rodent results are described in language that sounds clinical, the FDA compounding position is either omitted or reframed as a technicality, and the absence of human trials is presented as the compound being underappreciated rather than unproven. Recognising the pattern is more useful than memorising counterarguments.
A single question cuts through most of it: what has been shown in humans, in a controlled trial, measuring the outcome being promised. For BPC-157 the honest answer is nothing yet, and any seller unwilling to say so plainly has told you something about their sourcing. The checklist in verifying whether a peptide provider is legitimate covers the rest.
Frequently Asked Questions
Are there human studies on BPC-157?
Controlled human trial evidence for BPC-157 is essentially absent. Some early exploratory work in inflammatory bowel disease has been referenced in reviews, but nothing published amounts to an adequately powered controlled trial demonstrating a clinical outcome. Nearly every claim made for the compound rests on rodent studies.
Can a compounding pharmacy make BPC-157?
Licensed compounding pharmacies in the United States are not able to compound BPC-157. The FDA placed it in the category of bulk substances that raise significant safety risks for compounding use, which removed it from legitimate compounding practice. Any site presenting it as a compounded prescription product is describing something outside that system.
Is BPC-157 legal to buy?
BPC-157 is not an FDA-approved drug and is not available as a legitimate prescription or compounded product. Vendors sell it as research material labelled not for human consumption, which places it in a grey area rather than a clearly permitted category. The overview of how peptide legality works in the United States explains that distinction.
Is BPC-157 banned in sport?
BPC-157 is on the World Anti-Doping Agency Prohibited List and is banned in and out of competition. Athletes subject to testing should regard it as a violation, and anti-doping cases involving the compound have already occurred. Banned status reflects circulation and possible performance effects, not proof of efficacy.
Why does BPC-157 have so much research behind it if the evidence is weak?
BPC-157 has a large volume of published animal studies, which is not the same as strong evidence. Study count measures activity in a research area, while evidence quality depends on species, design, independence of the groups involved, and whether human outcomes were measured. On those dimensions the BPC-157 literature remains early.
Does Everhuman offer BPC-157?
Everhuman does not offer BPC-157 and does not facilitate access to it. Given the FDA compounding position, no legitimate telehealth provider in the United States can supply it as a compounded prescription, which is worth knowing before evaluating any site that claims otherwise.
The honest summary
BPC-157 is the clearest example in this category of a compound whose marketing has run far ahead of its evidence. Rodent research is extensive and some of it is interesting, human trial evidence is essentially absent, the FDA has placed it among substances raising significant safety risks for compounding, and it is prohibited in sport. Interesting mechanism, thin human evidence, and sold almost entirely outside the licensed system describes it accurately.
Saying that calmly is more useful than either promoting or condemning it. Anyone weighing this category is better served by understanding how the evidence is built than by any single verdict, and the companion reference on what is actually known about TB-500 and thymosin beta-4 shows the same pattern in a compound BPC-157 is usually sold beside.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology. 2021. PMID 34267654.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011. PMID 21030672.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID 41966639.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.